Kelly L Hayward
Overview
Explore the profile of Kelly L Hayward including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayward K, Weersink R, Bernardes C, McIvor C, Rahman T, Skoien R, et al.
Drugs Real World Outcomes
. 2023 Oct;
10(4):605-618.
PMID: 37828144
Background: Safe and appropriate use of medicines is essential to improve health outcomes in cirrhosis. However, little is known about the number and type of medicines dispensed to people with...
2.
Gracen L, Muthukumara W, Aikebuse M, Russell A, OBeirne J, Irvine K, et al.
Ann Hepatol
. 2023 Jul;
28(6):101142.
PMID: 37468097
Introduction And Objectives: Among people with type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) is very common and has an increased risk of clinically significant liver disease. The use...
3.
Valery P, Bernardes C, Hayward K, Hartel G, Haynes K, Gordon L, et al.
BMC Gastroenterol
. 2022 Jul;
22(1):340.
PMID: 35836105
Background: Optimal management of cirrhosis is complex, and patients often lack knowledge and skills, which can affect self-management. We assessed patient knowledge about cirrhosis and examined whether knowledge was associated...
4.
Gracen L, Hayward K, Irvine K, Valery P, Powell E
J Hepatol
. 2022 Jun;
77(4):1219-1221.
PMID: 35764234
No abstract available.
5.
Hayward K, Bansal V, Valery P, Irvine K, Wright P, Tallis C, et al.
Hepatol Commun
. 2022 May;
6(11):3281-3282.
PMID: 35560798
No abstract available.
6.
Gracen L, Hayward K, Aikebuse M, Russell A, OBeirne J, McPhail S, et al.
BMC Health Serv Res
. 2022 Apr;
22(1):487.
PMID: 35413987
Background: Non-alcoholic fatty liver disease (NAFLD) is an emerging epidemic that affects approximately half of all people with type 2 diabetes. Those with type 2 diabetes are a high-risk NAFLD...
7.
Gracen L, Hayward K, Aikebuse M, Williams S, Russell A, OBeirne J, et al.
Diabet Med
. 2022 Jan;
39(6):e14799.
PMID: 35100462
Aims: We explored barriers and facilitators to the implementation of nonalcoholic fatty liver disease (NAFLD) pathway for people with diabetes to identify determinants of behaviour surrounding the diagnosis, assessment and...
8.
Hayward K, Valery P, Patel P, Li C, Horsfall L, Wright P, et al.
Pharmaceuticals (Basel)
. 2021 Dec;
14(12).
PMID: 34959611
Discrepancies between the medicines consumed by patients and those documented in the medical record can affect medication safety. We aimed to characterize medication discrepancies and medication regimen complexity over time...
9.
Johnson A, Hayward K, Patel P, Horsfall L, Cheah A, Irvine K, et al.
Hepatol Commun
. 2021 Nov;
6(4):728-739.
PMID: 34783191
It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver-related...
10.
Johnson A, Hayward K
Aust Prescr
. 2021 Jul;
44(3):96-106.
PMID: 34211248
People with alcohol-associated liver disease often take medicines to manage complications of liver disease and comorbidities. However, patients may be at increased risk of drug-related harm Assessing the severity of...